RORγt inverse agonist 13 是一种口服有效的RORγt选择性反向激动剂，IC50为 63.8 nM。

RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist (IC50=63.8 nM), with improved drug-like properties[1].

RORγt inverse agonist 13 (Compound 3i) shows an inhibition of 76% at 0.3?μM in Th17 cell differentiation assay[1].

RORγt inverse agonist 13 (Compound 3i, 25 mg/kg, Orally, twice daily) demonstrats excellent in vivo PK profile in mice and good in vivo efficacy in an IMQ-induced psoriasis mice model[1].

2170477-75-3

DMSO:100 mg/mL (194.82 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years